慢性肾脏病-矿物质与骨异常(chronic kidney disease-mineral and bone disorders，CKD-MBD)是慢性肾脏病(chronic kidney disease，CKD)患者的常见且严重的并发症。地舒单抗(denosumab，DMab)是一种治疗绝经后骨质疏松的核因子-κB受体激活剂配体(receptor activator of nuclear factor-kappa B ligand，RANKL)的抑制剂，临床上已经应用于CKD非透析与透析、男性和女性患者，针对CKD-MBD使用DMab会对骨代谢指标、骨量、血管钙化产生影响，本文对CKD患者使用DMab治疗的安全性和有效性进行综述，以总结RANKL抑制剂治疗CKD-MBD的临床经验。

Chronic kidney disease-mineral and bone disorders (CKD-MBD) are common and serious complications in patients with CKD.  Denosumab (DMab) is an inhibitor of the receptor activator of nuclear factor-kappa B ligand (RANKL) used for the treatment of postmenopausal osteoporosis. It has been applied clinically for male or female CKD patients with or without dialysis. DMab used in the treatment of CKD-MBD may produce the effects on bone metabolism biomarkers, bone mass, and vascular calcification. Here we review the safety and efficacy of DMab in CKD patients and summarize the clinical experience of the RANKL inhibitor in the treatment of CKD-MBD.